Genotype-Guided Cannabinoid Regimen for Rapid Dose Personalization

Solution Overview

Problem

Existing methods for determining cannabinoid treatment regimens are inefficient and costly, often requiring months and thousands of dollars to find an effective dosage and ratio for conditions like pain, anxiety, and insomnia, without considering individual genetic variations in the endocannabinoid system.

Innovation Solution

A method and system that utilizes genetic testing to determine personalized cannabinoid treatment regimens by analyzing single nucleotide polymorphisms (SNPs) associated with the endocannabinoid system, adjusting dosages and ratios of cannabinoids like CBD and THC based on individual genetic responses and dependencies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional trial-and-error methods are used to determine cannabinoid treatment regimens, then treatment efficacy can be achieved, but the process takes months and costs thousands of dollars

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtime to determine regimen

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs genetic testing and SNP analysis before initiating cannabinoid treatment to predict individual responses. By analyzing genetic markers related to cannabinoid metabolism and receptor function in advance, the system determines optimal dosages and ratios before treatment begins, eliminating the need for months of trial-and-error adjustments.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses the patient's own genetic information to self-determine the appropriate treatment regimen. The genetic test results directly inform the dosage calculations without requiring external trial-and-error experimentation, allowing the treatment plan to be personalized and optimized based on inherent biological characteristics.

Inventive Principle:

Principle #25Self-service

2Measurement precision

If conventional trial-and-error methods are used to determine cannabinoid treatment regimens, then treatment efficacy can be achieved, but the cost reaches thousands of dollars

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtreatment cost

Core Design Contradiction:

Measurement precisionVSQuantity of substance

Solution Approach 1:

The patent performs genetic testing and SNP analysis before initiating cannabinoid treatment to predict individual responses. By analyzing genetic markers related to cannabinoid metabolism and receptor function in advance, the system determines optimal dosages and ratios before treatment begins, eliminating the need for months of trial-and-error adjustments.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses the patient's own genetic information to self-determine the appropriate treatment regimen. The genetic test results directly inform the dosage calculations without requiring external trial-and-error experimentation, allowing the treatment plan to be personalized and optimized based on inherent biological characteristics.

Inventive Principle:

Principle #25Self-service

3Ease of operation

If standardized cannabinoid dosages are used without genetic consideration, then treatment can be simplified, but individual genetic variations in the endocannabinoid system are ignored

Engineering Contradiction:

Improvetreatment simplicityVSAvoidgenetic personalization

Core Design Contradiction:

Ease of operationVSAdaptability or versatility

Solution Approach 1:

The patent applies the principle of local quality by customizing treatment parameters based on specific genetic characteristics of each patient. Rather than using a uniform approach, the system identifies and addresses individual genetic variations in cannabinoid metabolism enzymes, receptor genes, and transporters, tailoring the treatment to the specific biological profile of each patient's endocannabinoid system.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes treatment parameters (dosage, ratio of cannabinoids) based on genetic test results. The system adjusts dosing recommendations according to genetic variants that affect cannabinoid metabolism rate, receptor sensitivity, and transport efficiency, transforming a standardized approach into a personalized one through parameter modification.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260011426A1Method and system for providing a personalized cannabinoid treatment regimen

Publication Date: 2026.01.08 GREENWAY DNA INC

AI summary

Methods and systems for providing a personalized cannabinoid treatment regimen to a patient include obtaining genotypes of single nucleotide polymorphisms (SNPs) from a patient's genetic test and modifying base values, such as base dosages or base ratios, using weighting values reflecting the obtained genotypes to obtain regimen values for treating the patient. The regimen values take into account expected responses to cannabinoids based on patient genetic information.